NEW YORK (GenomeWeb News) – Cepheid announced after the close of the market on Thursday that its preliminary second-quarter earnings results are anticipated to beat consensus analyst estimates on the top and bottom lines.

For the three months ended June 30, the Sunnyvale, Calif.-based firm said that total revenues are expected to be about $96 million, which would beat Wall Street expectations of $92.2 million. It also would represent a 19 percent improvement over $81.0 million in revenues recorded in the second quarter of 2012.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: transcript patterns in drug-resistant cancer cells, function of high-altitude adaption gene, and more.

Monitoring gene expression changes could help sniff out athletes using performance-enhancing drugs, New Scientist says.

The University of Southern California lodges a cross-complaint in its legal dispute with the University of California, San Diego, over a large Alzheimer's disease project.

In PLOS this week: gene fusion in premature ovarian failure, population patterns in the Franciscana dolphin, and more.